Arabic Arabic English English French French German German
dark

Antengene Submits New Drug Application for Selinexor in Taiwan for the Treatment of Three Indications in Hematologic Malignancies

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has submitted a New Drug Application (NDA) to the Taiwan Food and Drug Administration (TFDA) for selinexor, Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Hillstream BioPharma Expands the Scientific Advisory Board with the Addition of Leading Innovator in the Study of Ferroptosis and Cancer, Scott Dixon, Ph.D.

Next Post

Centene Announces Organizational Enhancements, Establishes The Office Of The President

Related Posts
Total
0
Share